Medical Tidbits,Allergan Launches Bold Initiative to Help U.S. Military Servicewomen Access LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at Military Treatment Facilities

breaking medical news

PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today launched a bold initiative, “LILETTA Access on the Front Line™”, aimed at helping to knock down barriers to intrauterine device (IUD) access for women in the military.  According to the Veterans Affairs (VA) Federal Supply Schedule (FSS), long-acting reversible contraceptives (LARCs), including IUDs, currently cost the military in the range of $330 to $650. Beginning in 2016, LILETTA is available at an FSS price of $55.83 to Military Treatment Facilities and VA hospitals nationwide. With LILETTA, Allergan meets the need for an affordable LARC option for women on the front lines, as well as the family members of those in service and our nation’s female veterans. Allergan’s initiative also includes an educational effort to raise contraception awareness among healthcare providers treating U.S. military servicewomen. read more

Lilly’s Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis

PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programs to help ensure eligible patients have access to Taltz and available resources.

Taltz was approved by the U.S. FDA in March 2016 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy or phototherapy. Taltz should not be used in patients with previous hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. Taltz is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.1 read more

Medtronic Expands MRI-Compatible Portfolio with FDA Clearance of StrataMR(TM) Shunt System

Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) clearance of StrataMR(TM) valves and shunts, an addition to Medtronic’s family of Strata® Adjustable Valve Systems used in the treatment of patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. The StrataMR system is intended to maintain its performance level setting during magnetic resonance imaging (MRI) exposure when scanned in accordance with labeling. read more


AstraZeneca today announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited (“Takeda”). The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

  • 19 Genentech medicines are included in more than 200 abstracts during ASCO 2016
  • New results for cancer immunotherapy atezolizumab in bladder cancer and other cancer types
  • Early results for atezolizumab in combination with targeted medicines and the investigational cancer immunotherapy MOXR0916, an OX40 agonist
  • Superiority results from Phase III study comparing Alecensa® (alectinib) to crizotinib    read more

IMS Health and Quintiles to Merge

Quintiles IMS to Become Industry-Leading Information and Technology-Enabled Healthcare Service Provider

All-Stock Transaction with Combined 2015 Revenue of $7.2 Billion and Combined Equity Market Capitalization of $17.6 Billion read more

Ferring Pharmaceuticals Announces Approval for NOCDURNA®, a New Therapeutic Option for the Treatment of Adults Waking Multiple Times to Urinate at Night

SAINT PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals, today announced that NOCDURNA® (desmopressin), has received approval in the EU, for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.  read more

Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen’s Paris-Saclay Campus

ONCODESIGN (Alternext: ALONC) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that they have entered into a strategic partnership in oncology. Under this new agreement, Oncodesign will handle pre-clinical pharmacology for Ipsen’s oncology research programs. In addition, some of Oncodesign’s teams are moving to Ipsen’s largest R&D center at the Paris-Saclay hub, putting them at the heart of an ecosystem made up of research scientists, leading educational institutions, research facilities and cutting-edge industrial groups. For the past 20 years, Oncodesign and Ipsen have worked together on R&D projects based on a service and co-development relationship, before sealing a drug discovery .

Study Proves Long-Term Effectiveness of Avastin and Lucentis for Treating Major Cause of Blindness

PRNewswire-USNewswire/ — New results from a landmark clinical trial have confirmed the long-term effectiveness and safety of the drugs Avastin and Lucentis for treating age-related macular degeneration, a major cause of blindness. The study found that half of eyes treated with either drug after five years maintained vision typically considered good enough to drive and read. The researchers called the results “remarkable” given that before these drugs were available the majority of people with the condition would have gone legally blind. The study is being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. read more

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!





Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.